Global Celiac Disease Market Spotlight 2017-2026 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Celiac Disease” report has been added to ResearchAndMarkets.com’s
offering.

This Market Spotlight report covers the Celiac Disease market,
comprising key pipeline drugs, clinical trials, upcoming events, patent
information, a 10-year disease prevalence forecast, and licensing and
acquisition deals.

Key Takeaways

• The report estimates that in 2017, there were approximately 89.9
  million prevalent cases of celiac disease worldwide, and forecasts
  that number to increase to 98.8 million prevalent cases by 2026.
• Prevalence of celiac disease is highest in Europe and Northern
  America, and lowest in Africa and Oceania.
• All industry-sponsored drugs in active clinical development for celiac
  disease are in Phase I or Phase II. Therapies in development for
  celiac disease focus on targets such as gluten, interleukin-15,
  interleukin-15 receptor, zonulin and zonulin receptor, immune system,
  and T-cell receptor. Pipeline drugs for celiac disease are
  administered orally, as well as via the subcutaneous, intradermal, and
  intravenous routes.
• High-impact upcoming events for drugs in the celiac disease space
  comprise topline Phase III trial results for INN-202. The overall
  likelihood of approval of a Phase I autoimmune/immunology asset is
  14.5%, and the average probability a drug advances from Phase III is
  68%. Drugs, on average, take 8.7 years from Phase I to approval in the
  overall autoimmune/immunology space
• There have been five licensing and asset acquisition deals involving
  celiac disease drugs during 2014-19. The largest deal during the
  period was the $170m licensing and co-development agreement signed in
  2018 between Amgen and Provention Bio, for the development of
  anti-IL-15 antibody AMG 714 for the treatment of gluten-free diet
  non-responsive celiac disease.
• The distribution of clinical trials across Phase I-III indicates that
  the vast majority of trials for celiac disease have been in the mid
  and late phases of development, with 91% of trials in Phase II-III,
  and only 9% in Phase I.
• The US has a substantial lead in the number of celiac disease clinical
  trials globally. Innovate Biopharmaceuticals has the highest number of
  completed trials for celiac disease, with six trials, and also leads
  industry sponsors with the highest number of clinical trials for
  celiac disease overall.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

Subtypes

TREATMENT

EPIDEMIOLOGY

PIPELINE DRUGS

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

Amgen Links With Provention For AMG 714 In Celiac Disease

PARENT PATENTS

CLINICAL TRIAL LANDSCAPE

Sponsors by status

Sponsors by phase

BIBLIOGRAPHY

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/tdhx2v

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Immune
Disorders Drugs, Gastrointestinal
Drugs